Uric Acid Is Associated With Inflammation, Coronary Microvascular Dysfunction, and Adverse Outcomes in Postmenopausal Women

Overview

Journal Hypertension

Date 2016 Dec 21

PMID 27993955

Citations 41

Authors

Megha Prasad

Eric L Matteson

Joerg Herrmann

Rajiv Gulati

Charanjit S Rihal

Lilach O Lerman

Amir Lerman

Affiliations

Soon will be listed here.

Abstract

Uric acid is a risk factor for coronary artery disease in postmenopausal women, but the association with inflammation and coronary endothelial dysfunction (CED) is not well defined. The aim of this study was to determine the relationship of serum uric acid (SUA), inflammatory markers, and CED. In this prospective cohort study, SUA, high-sensitivity C-reactive protein levels, and neutrophil count were measured in 229 postmenopausal women who underwent diagnostic catheterization, were found to have no obstructive coronary artery disease, and underwent coronary microvascular function testing, to measure coronary blood flow response to intracoronary acetylcholine. The average age was 58 years (interquartile range, 52-66 years). Hypertension was present in 48%, type 2 diabetes mellitus in 5.6%, and hyperlipidemia in 61.8%. CED was diagnosed in 59% of postmenopausal women. Mean uric acid level was 4.7±1.3 mg/dL. Postmenopausal women with CED had significantly higher SUA compared with patients without CED (4.9±1.3 versus 4.4±1.3 mg/dL; P=0.02). There was a significant correlation between SUA and percent change in coronary blood flow to acetylcholine (P=0.009), and this correlation persisted in multivariable analysis. SUA levels were significantly associated with increased neutrophil count (P=0.02) and high-sensitivity C-reactive protein levels (P=0.006) among patients with CED, but not among those without CED. SUA is associated with CED in postmenopausal women and may be related to inflammation. These findings link SUA levels to early coronary atherosclerosis in postmenopausal women.

Citing Articles

The Role of Circulating Biomarkers in Patients with Coronary Microvascular Disease.

Quarta R, Martino G, Romano L, Lopes G, Greco F, Spaccarotella C Biomolecules. 2025; 15(2).

PMID: 40001480 PMC: 11853534. DOI: 10.3390/biom15020177.

The association of perioperative serum uric acid variation with in-hospital adverse outcomes in coronary artery bypass grafting patients.

Gao J, Cheng Y Front Cardiovasc Med. 2024; 11:1364744.

PMID: 39411174 PMC: 11475021. DOI: 10.3389/fcvm.2024.1364744.

Serum Uric Acid and Hyperuricemia Associate with Coronary Artery Disease among Postmenopausal Women.

Guo Q, Liu Y, Feng X, Yang J, Zhai G, Zhou Y Rev Cardiovasc Med. 2024; 23(7):222.

PMID: 39076919 PMC: 11266768. DOI: 10.31083/j.rcm2307222.

Associations of serum uric acid variability with neuroimaging metrics and cognitive decline: a population-based cohort study.

Lv H, Sun J, Zhang T, Hui Y, Li J, Zhao X BMC Med. 2024; 22(1):256.

PMID: 38902722 PMC: 11188528. DOI: 10.1186/s12916-024-03479-9.

Non-Interventional Weight Changes Are Associated with Alterations in Serum Uric Acid Levels.

Weinstein S, Maor E, Bleier J, Kaplan A, Hod T, Leibowitz A J Clin Med. 2024; 13(8).

PMID: 38673586 PMC: 11051435. DOI: 10.3390/jcm13082314.

References

Nomura J, Busso N, Ives A, Matsui C, Tsujimoto S, Shirakura T . Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice. Sci Rep. 2014; 4:4554. PMC: 3971401. DOI: 10.1038/srep04554. View

Guedes M, Esperanca A, Pereira A, Rego C . What is the effect on cardiovascular events of reducing hyperuricemia with allopurinol? An evidence-based review. Rev Port Cardiol. 2014; 33(11):727-32. DOI: 10.1016/j.repc.2014.06.002. View

Spoon D, Lerman A, Rule A, Prasad A, Lennon R, Holmes D . The association of serum uric acid levels with outcomes following percutaneous coronary intervention. J Interv Cardiol. 2010; 23(3):277-83. DOI: 10.1111/j.1540-8183.2010.00555.x. View

Maniu C, Higano S, Lerman A . Assessing coronary endothelial dysfunction. Circulation. 2002; 106(11):e48; discussion e48. DOI: 10.1161/01.cir.0000030083.02775.d7. View

Prasad M, McBane R, Reriani M, Lerman L, Lerman A . Coronary endothelial dysfunction is associated with increased risk of venous thromboembolism. Thromb Res. 2016; 139:17-21. DOI: 10.1016/j.thromres.2015.12.024. View

Butler R, Morris A, Belch J, Hill A, Struthers A . Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension. 2000; 35(3):746-51. DOI: 10.1161/01.hyp.35.3.746. View

Dai X, Wei L, Ma L, Chen H, Zhang Z, Ji Z . Serum uric acid and its relationship with cardiovascular risk profile in Chinese patients with early-onset coronary artery disease. Clin Rheumatol. 2015; 34(9):1605-11. DOI: 10.1007/s10067-015-2878-1. View

Chen J, Lan J, Cheng C, Liang W, Lin H, Tsay G . Effect of Urate-Lowering Therapy on All-Cause and Cardiovascular Mortality in Hyperuricemic Patients without Gout: A Case-Matched Cohort Study. PLoS One. 2015; 10(12):e0145193. PMC: 4684295. DOI: 10.1371/journal.pone.0145193. View

Niskanen L, Laaksonen D, Nyyssonen K, Alfthan G, Lakka H, Lakka T . Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004; 164(14):1546-51. DOI: 10.1001/archinte.164.14.1546. View

10.

Sciacqua A, Perticone M, Tassone E, Cimellaro A, Miceli S, Maio R . Uric acid is an independent predictor of cardiovascular events in post-menopausal women. Int J Cardiol. 2015; 197:271-5. DOI: 10.1016/j.ijcard.2015.06.069. View

11.

Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M . Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol. 2004; 94(7):932-5. DOI: 10.1016/j.amjcard.2004.06.032. View

12.

Zoccali C, Maio R, Mallamaci F, Sesti G, Perticone F . Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol. 2006; 17(5):1466-71. DOI: 10.1681/ASN.2005090949. View

13.

Strasak A, Kelleher C, Brant L, Rapp K, Ruttmann E, Concin H . Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. Int J Cardiol. 2008; 125(2):232-9. DOI: 10.1016/j.ijcard.2007.11.094. View

14.

Nicholls A, Snaith M, SCOTT J . Effect of oestrogen therapy on plasma and urinary levels of uric acid. Br Med J. 1973; 1(5851):449-51. PMC: 1588487. DOI: 10.1136/bmj.1.5851.449. View

15.

Hashimoto M, Akishita M, Eto M, Ishikawa M, Kozaki K, Toba K . Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation. 1995; 92(12):3431-5. DOI: 10.1161/01.cir.92.12.3431. View

16.

de Jager J, Dekker J, Kooy A, Kostense P, Nijpels G, Heine R . Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: the Hoorn Study. Arterioscler Thromb Vasc Biol. 2006; 26(5):1086-93. DOI: 10.1161/01.ATV.0000215951.36219.a4. View

17.

Matsuzawa Y, Lerman A . Endothelial dysfunction and coronary artery disease: assessment, prognosis, and treatment. Coron Artery Dis. 2014; 25(8):713-24. PMC: 4220301. DOI: 10.1097/MCA.0000000000000178. View

18.

Choi B, Prasad A, Gulati R, Best P, Lennon R, Barsness G . Coronary endothelial dysfunction in patients with early coronary artery disease is associated with the increase in intravascular lipid core plaque. Eur Heart J. 2013; 34(27):2047-54. PMC: 3710580. DOI: 10.1093/eurheartj/eht132. View

19.

Park J, Kang S, Ahn C, Cha B, Kim K, Lee H . Relationships between serum uric acid, adiponectin and arterial stiffness in postmenopausal women. Maturitas. 2012; 73(4):344-8. DOI: 10.1016/j.maturitas.2012.09.009. View

20.

Mosca L, Banka C, Benjamin E, Berra K, Bushnell C, Dolor R . Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007; 115(11):1481-501. DOI: 10.1161/CIRCULATIONAHA.107.181546. View